tolvaptan has been researched along with Pain in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Blais, JD; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Grantham, JJ; Higashihara, E; Ouyang, J; Perrone, RD; Torres, VE | 1 |
Blais, JD; Casteleijn, NF; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Higashihara, E; Leliveld, AM; Ouyang, J; Perrone, RD; Torres, VE | 1 |
Bae, KT; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Grantham, JJ; Higashihara, E; Krasa, HB; Meijer, E; Ouyang, JJ; Perrone, RD; Torres, VE | 1 |
3 trial(s) available for tolvaptan and Pain
Article | Year |
---|---|
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Topics: Adult; Albuminuria; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Hypernatremia; Hypertension; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Pain; Polycystic Kidney, Autosomal Dominant; Severity of Illness Index; Tolvaptan | 2016 |
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Humans; Incidence; Kidney Diseases; Male; Pain; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Single-Blind Method; Time Factors; Tolvaptan | 2017 |
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Topics: Adolescent; Adult; Albuminuria; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Management; Double-Blind Method; Female; Humans; Male; Middle Aged; Pain; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Receptors, Vasopressin; Tolvaptan; Treatment Outcome; Young Adult | 2011 |